SCHEMBL5546787

SCHEMBL5546787

CCOC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(CCN2CCCCC2=O)c1=O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
ALDH1A1 P00352 6/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 5/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.38
MAPT P10636 1/20 0.37
PKM P14618 1/20 0.37
XIAP P98170 1/20 0.36
BIRC2 Q13490 1/20 0.36
SIRT2 Q8IXJ6 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
PER2 O15055 1/20 0.34
GAA P10253 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4998773 0.98 PDE3B (0.43) PDE3BPDE3AALDH1A1SMN1; SMN2KDM4E
SCHEMBL5539167 0.95 KDM4E (0.41) PDE3BPDE3AALDH1A1SMN1; SMN2KDM4E
SCHEMBL5544647 0.95 KDM4E (0.41) PDE3BPDE3AALDH1A1SMN1; SMN2KDM4E
SCHEMBL5545740 0.94 SIRT2 (0.42) PDE3BPDE3AALDH1A1SMN1; SMN2KDM4E
SCHEMBL5538517 0.90 KDM4E (0.44) PDE3BPDE3AALDH1A1SMN1; SMN2KDM4E
SCHEMBL5545562 0.88 CNR2 (0.39) ALDH1A1SMN1; SMN2XIAPBIRC2
SCHEMBL27667068 0.88 GRM2 (0.41) ALDH1A1SMN1; SMN2KDM4EXIAPBIRC2
SCHEMBL4998803 0.87 XIAP (0.39) ALDH1A1SMN1; SMN2KDM4EMAPTXIAP
SCHEMBL5546734 0.86 XIAP (0.39) ALDH1A1SMN1; SMN2XIAPBIRC2
SCHEMBL5546910 0.86 ALDH1A1 (0.39) PDE3BPDE3AALDH1A1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 PDE3B 3560/4885PDE3A 3339/4885ALDH1A1 3812/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 PDE3B 3316/4885PDE3A 3100/4885ALDH1A1 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.